benzyloxycarbonyl-phe-ala-fluormethylketone has been researched along with vanitiolide in 1 studies
| Studies (benzyloxycarbonyl-phe-ala-fluormethylketone) | Trials (benzyloxycarbonyl-phe-ala-fluormethylketone) | Recent Studies (post-2010) (benzyloxycarbonyl-phe-ala-fluormethylketone) | Studies (vanitiolide) | Trials (vanitiolide) | Recent Studies (post-2010) (vanitiolide) |
|---|---|---|---|---|---|
| 5 | 0 | 5 | 15 | 0 | 10 |
| Protein | Taxonomy | benzyloxycarbonyl-phe-ala-fluormethylketone (IC50) | vanitiolide (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 4.6 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 2.96 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
1 other study(ies) available for benzyloxycarbonyl-phe-ala-fluormethylketone and vanitiolide
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |